Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02966275
Other study ID # 2016P000710
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date December 2017

Study information

Verified date November 2018
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to test our automated hypoglycemia prevention and treatment device (glucagon-only bionic pancreas) in subjects that have undergone post-bariatric surgery that are experiencing symptoms of hypoglycemia.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Age 21 years or older with a gastric bypass for more than 1 year.

- Post-bariatric hypoglycemia with prior episodes of neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose. Other therapies will not exclude a subject as long as the therapy is continued during the study.

- Otherwise healthy (mild chronic disease such as asthma, hypertension, and depression will be allowed if well controlled).

- Self-reported frequency of documented hypoglycemia (BG < 60 mg/dl verified by capillary blood glucose measurements) of at least 2 times per week.

Exclusion Criteria:

- Unable to provide informed consent.

- Unable to comply with study procedures.

- Current participation in another hypoglycemia related clinical trial other than one that is primarily observational in nature.

- Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception.

- Use of insulin and/or insulin secretogues as sulfonylurea, metglitides, and glitazones.

- History of cystic fibrosis, pancreatitis, type 1 diabetes or other pancreatic disease.

- End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).

- Any known liver or biliary disease including cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, any form of viral hepatitis.

- Congestive heart failure (established history of CHF, paroxysmal nocturnal dyspnea, or orthopnea).

- Acute illness or exacerbation of chronic illness at the time of the study.

- Known insulinoma or predominantly fasting pattern of hypoglycemia

- Adrenal insufficiency. Congenital hyperinsulinemia presenting with hypoglycemia during infancy.

- History of pheochromocytoma. Fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor:

- Paroxysms of tachycardia, pallor, or headache.

- Personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease.

- Episodic or treatment refractory (requiring 4 or more medications to achieve normotension) hypertension.

- Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and/or any psychiatric hospitalization in the last year).

- Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days) or substance abuse (any use within the last 6 months of controlled substances without a prescription).

- Unwilling or unable to refrain from drinking more than two drinks in an hour or more than four drinks in a day during the trial.

- Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference.

- History of adverse reaction to glucagon (including allergy) besides nausea and vomiting.

- Unwilling or unable to completely avoid acetaminophen during the study period.

- Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Glucagon-only bionic pancreas - glucagon
A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
Glucagon-only bionic pancreas - placebo
A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts General Hospital Joslin Diabetes Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Over the Curve and <60 mg/dl (CGM) Measured in mg/dl *Min The measure for area over the curve is used when an integrated assessment (e.g., a measurement of something over a specific amount of time) is more useful in understanding a phenomenon. To calculate this measure, a method of approximation is often used. One way would be to estimate the curve via curve-fitting techniques. For this outcome, using area over the curve and <60mg/dl provides a more robust method of calculating amount of hypoglycemia (by including more severe degrees of hypoglycemia in the product of mg/dl*min as opposed to percentage of time below 60mg/dl. 14 days
Secondary Mean Continuous Glucose Monitor (CGM) Glucose 2 weeks
Secondary Percentage of Time With CGM Glucose Less Than 60 mg/dl Overnight (11:00 PM - 7:00 AM) 14 days
Secondary Percentage of Time With CGM Glucose Less Than 60 mg/dl During Daytime ( 7:00 AM-11:00 PM) 14 days
Secondary Percentage of Time Spent Within the Glucose Range 70-120 mg/dl 14 days
Secondary Percentage of Time Spent Within the Glucose Range 70-180 mg/dl 14 days
Secondary Percentage of Time Spent Within the Glucose Range >180 mg/dl 14 days
Secondary Fraction of Time Spent Within the Glucose Range >250 mg/dl 2 weeks
Secondary Mean Absolute Relative Deviation (MARD) of CGM vs. All StatStrip Xpress BG Measurements MARD is computed using the difference between the CGM readings and the values measured at the same time by the reference measurement system. The mean (or average) of all the absolute relative deviations produces the MARD. In this study, the reference measurement system was the StatStrip Xpress meter, to which the CGM values were compared. 14 days
Secondary Number of Carbohydrate Interventions for Hypoglycemia Per Day Number of carbohydrate interventions for hypoglycemia per day calculated from daily email survey 14 days
Secondary Total Number of Grams of Carbohydrate Taken for Hypoglycemia Per Day Calculated from daily email survey 14 days
Secondary Total Glucagon Dosing (mcg/kg/24 Hours) 2 weeks
Secondary Number of Symptomatic Hypoglycemia Events Per Day Number of symptomatic hypoglycemia events per day calculated from daily email survey 14 days
Secondary Percentage of Days When Participants Correctly Guessed Intervention (Glucagon vs Placebo) Out of a Total of 14 Days. 2 weeks
Secondary Number of Days With Nausea Number of days with nausea calculated from daily survey 14 days
Secondary Severity of Nausea on Daily E-mail Survey The visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. We used a simple VAS is a straight horizontal line of fixed length measuring 0-100mm with subscale markings every 10mm. The ends are defined as the extreme limits of the parameter to be measured (nausea) orientated from the left (least severity or 0) to the right (most severity or 100mm). Subjects can mark their response anywhere from 0 to 100mm. The mean severity of nausea for the group in each arm was calculated by averaging all responses in either arm. 14 days
See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Completed NCT03667053 - Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children Phase 3
Active, not recruiting NCT03422471 - Hypoglycemia and Autonomic Nervous System Function- B2 N/A
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05597605 - The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects N/A
Not yet recruiting NCT05990933 - Role of Adrenaline in in the Inflammatory Response in Diabetes N/A
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Not yet recruiting NCT02909881 - Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02213003 - Allogeneic Islet Cells Transplanted Onto the Omentum Phase 1/Phase 2
Completed NCT01176656 - Hypoglycemia: Physician and Patient Perspectives N/A
Completed NCT01147276 - Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes Phase 4
Completed NCT00998374 - Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge N/A
Terminated NCT01225159 - Tight Glycaemic Control During Cardiac Surgery N/A
Completed NCT00373854 - Study of How Low Blood Sugar Affects the Way Blood Vessels Work N/A
Completed NCT00285233 - Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes Phase 1/Phase 2
Recruiting NCT05916131 - Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management. N/A
Terminated NCT04026750 - Insulin Tolerance Test Study in Patients With Type 1 Diabetes Phase 1
Completed NCT05133765 - The SMART B Exercise Study :''The SMART Study'' N/A
Recruiting NCT04192422 - DiGESTnewborn Study